Compstatin analogs with improved activity
CA 2833202 C · Owner: The Trustees Of The University Of Pennsylvania · Inventors: Lambris, John D.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compounds comprising peptides and peptidomimetics capable of binding the C3 protein and inhibiting complement activation are disclosed. These compounds display , improved complement activation-inhibitory activity as compared with currently available compounds. Isolated nucleic molecules encoding the peptides are also disclosed. Also disclosed is a method for making the compounds and use of such compounds, such as artificial organ, artificial implant or tubing coated with , a , compound of the invention that inhibits complement activation. A method for making , the compounds is disclosed which includes synthesizing the peptide by condensation , of the amino acid residues or analogs …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 22, 2003 and granted August 1, 2017. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 22, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 22, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.